Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration

References

• Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002; 79: 123–135
   PubMed Web of Science ®Google Scholar
• Beall HD, Sloan KB. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyl-5-FU prodrugs. Int J Pharm 2001; 217: 127–137
   PubMed Web of Science ®Google Scholar
• Campbell PI. Toxicity of some charged lipids used in liposomes preparation. Cytobios 1983; 37: 21–26
   PubMedGoogle Scholar
• Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori 2003; 89: 237–249
   PubMed Web of Science ®Google Scholar
• Delie F. Evaluation of nano- and microparticles uptake by the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 221–233
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res 1996; 13: 1838–1845
   PubMed Web of Science ®Google Scholar
• Deshmukh DS, Bear WD, Brockerhoff H. Can intact liposomes be absorbed in the gut?. Life Sci 1980; 28: 239–242
   Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990; 11: 205–214
   Web of Science ®Google Scholar
• Elhissi AM, O'Neill MA, Roberts SA, Taylor KM. A calorimetric study of dimyristoylphosphatidylcholine phase transitions and steroid–liposomes interactions for liposomes prepared by thin film and proliposomes methods. Int J Pharm 2006; 320: 124–130
   PubMed Web of Science ®Google Scholar
• Fahr A, Van Hoogevest P, May S, Bergstrand N, S Leigh ML, May S. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: Consequences for drug delivery. Eur J Pharm Sci 2005; 26: 251–265
   PubMed Web of Science ®Google Scholar
• Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Release 1995; 36: 39–46
   Web of Science ®Google Scholar
• Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228
   PubMed Web of Science ®Google Scholar
• Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems—clinical applications. Acta Pharm 2005; 55: 1–25
   PubMedGoogle Scholar
• Kaiser N, Kimpfler A, Massing U, Burger AM, Fiebig HH, Brandl M, Schubert R. 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: Entrapment and release properties. Int J Pharm 2003; 256: 123–131
   PubMed Web of Science ®Google Scholar
• Kametani T, Kigasawa K, Hiiragi M, Wakisaka K, Haga S, Nagamatsu Y, Sugi H, Fukawa K, Irino O, Yamamoto T, Nishimura N, Taguchi A, Okada T, Nakayama M. Studies on the Synthesis of Chemotherapeutics 10 Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives. J Med Chem 1980; 23: 1324–1329
   PubMed Web of Science ®Google Scholar
• Leigh M, van Hoogevest P, Tiemessen H. Optimising the oral bioavailability of the poorly water-soluble drug cyclosporin A using membrane lipid technology. Drug Deliv Syst Sci 2001; 1: 73–77
   Google Scholar
• Li Y, Mitra AK. Effect of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm Res 1996; 13: 76–79
   PubMed Web of Science ®Google Scholar
• Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001; 90: 667–680
   PubMed Web of Science ®Google Scholar
• Lidgate DM, Felgner PL, Fleitman JS, Whatley J, Fu RC. In vitro and in vivo studies evaluating a liposomes system for drug solubilization. Pharm Res 1988; 5: 759–764
   PubMed Web of Science ®Google Scholar
• Liu D, Mori A, Huang L. Role of liposomes size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposome. Biochim Biophys Acta 1992; 1104: 95–101
   PubMed Web of Science ®Google Scholar
• Liu L, Jin P, Cheng M, Zhang G, Zhang FB. FB5-Fluorouracil-loaded self-assembled pH-sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chin J Chem Eng 2006; 14: 377–382
   Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91–97
   Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005; 107: 215–228
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990; 50: 575–579
   PubMed Web of Science ®Google Scholar
• Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999; 40: 75–87
   PubMed Web of Science ®Google Scholar
• Pauletti GM, Wunderli-Allenspach H. Partition coefficients in vitro: Artificial membranes as a standardized distribution model. Eur J Pharm Sci 1994; 1: 273–282
   Web of Science ®Google Scholar
• Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ, van der Wilt CL, Meyer S, Pinedo HM. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 1993; 269: 276
   Google Scholar
• Plember van Balen G, Caron G, Ermondi G, Pagliara A, Grandi T, Bouchard G, Fruttero R, Carrupt PA, Testa B. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res 2001; 18: 694–701
   PubMed Web of Science ®Google Scholar
• Portney NG, Ozkan M. Nano-oncology: Drug delivery, imaging, and sensing. Anal Bioanal Chem 2005; 384: 620–630
   Web of Science ®Google Scholar
• Pupo E, Padrón A, Santana E, Sotolongo J, Quintana D, Dueñas S, Duarte C, de la Rosa MC, Hardy E. Preparation of plasmid DNA-containing liposomes using a high-pressure homogenizationextrusion technique. J Control Release 2005; 104: 379–396
   PubMed Web of Science ®Google Scholar
• Sun WT, Huang GH, Ye JS, Zhang N. Determination encapsulation efficiencies of liposomes and nanoliposomes by protamine aggregation method. Chin Pharm J 2006; 41: 43–47
   Google Scholar
• Van Balen GP, Martinet CM, Caron G, Bouchard G, Reist M, Carrupt PA, Fruttero R, Gasco A, Testa B. Liposome/water lipophilicity: Methods, information content, and pharmaceutical applications. Med Res Rev 2004; 24: 299–324
   PubMed Web of Science ®Google Scholar
• Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255: 13–32
   PubMed Web of Science ®Google Scholar
• Yang YB, Tang ZQ, Zhang P. The pharmacokinetics of atofluding in cancer patients. Chin J New Drugs 2004; 10: 196–198
   Google Scholar
• Yu HY, Liu RF. Hepatic uptake and tissue distribution of liposomes: Influence of vesicle size. Drug Dev Ind Pharm 1994; 20: 557–574
   Web of Science ®Google Scholar
• Zhou W, Ping QN, Wang LJ. Influence of particle size on the tissue distribution of hydroxycamptothecin liposomes. J China Pharm Univ 2005; 36: 125–128
   Google Scholar